Overview

A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer

Status:
Active, not recruiting

Trial end date:
2022-08-02

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to evaluate the safety and efficacy of abemaciclib plus tamoxifen or abemaciclib alone in women with previously treated hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), metastatic breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Antidiarrheals
Loperamide
Tamoxifen